SLNO — Soleno Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $3.63bn
- $3.39bn
- 47
- 15
- 86
- 47
Annual income statement for Soleno Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 36.3 | 31.5 | 24.4 | 41.4 | 188 |
| Operating Profit | -36.3 | -31.5 | -24.4 | -41.4 | -188 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -24.6 | -30.9 | -24.1 | -39 | -176 |
| Net Income After Taxes | -24.6 | -30.9 | -24.1 | -39 | -176 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -24.6 | -30.9 | -24.1 | -39 | -176 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -24.6 | -30.9 | -24.1 | -39 | -176 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.9 | -5.81 | -2.87 | -2.36 | -4.38 |